Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuelle Verger

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Blood Advances|January 14, 2022
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibitionNabih Maslah, Emmanuelle Verger, Stéphane Giraudier, et al.
Pharmacogenetics and Genomics|March 11, 2010
Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell diseaseSandrine Laurance, François-Xavier Pellay, Omer P Dossou-Yovo, et al.
Annals of Hematology|September 28, 2018
Next-generation sequencing for JAK2 mutation testing: advantages and pitfallsNabih Maslah, Emmanuelle Verger, Marie-Helene Schlageter, et al.
British Journal of Haematology|September 25, 2021
Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurementNabih Maslah, Odonchimeg Ravdan, Louis Drevon, et al.
The Journal of Molecular Diagnostics : JMD|November 25, 2015
Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow TransplantationOlivier Mansier, Marina Migeon, Arnaud Saint-Lézer, et al.
Blood Cancer Journal|October 6, 2018
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivoEmmanuelle Verger, Juliette Soret-Dulphy, Nabih Maslah, et al.
The Journal of Experimental Medicine|October 19, 2020
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PMLTracy Dagher, Nabih Maslah, Valérie Edmond, et al.
Blood|October 22, 2015
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutationsEmmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, et al.
Thrombosis and Haemostasis|August 14, 2018
Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic FeaturesAnna Guadall, Elodie Lesteven, Gil Letort, et al.
Haematologica|September 7, 2019
Synergistic effects of PRIMA-1<sup>Met</sup> (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemiaNabih Maslah, Norman Salomao, Louis Drevon, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Blood Advances|January 14, 2022
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibitionNabih Maslah, Emmanuelle Verger, Stéphane Giraudier, et al.
Pharmacogenetics and Genomics|March 11, 2010
Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell diseaseSandrine Laurance, François-Xavier Pellay, Omer P Dossou-Yovo, et al.
Annals of Hematology|September 28, 2018
Next-generation sequencing for JAK2 mutation testing: advantages and pitfallsNabih Maslah, Emmanuelle Verger, Marie-Helene Schlageter, et al.
British Journal of Haematology|September 25, 2021
Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurementNabih Maslah, Odonchimeg Ravdan, Louis Drevon, et al.
The Journal of Molecular Diagnostics : JMD|November 25, 2015
Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow TransplantationOlivier Mansier, Marina Migeon, Arnaud Saint-Lézer, et al.
Blood Cancer Journal|October 6, 2018
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivoEmmanuelle Verger, Juliette Soret-Dulphy, Nabih Maslah, et al.
The Journal of Experimental Medicine|October 19, 2020
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PMLTracy Dagher, Nabih Maslah, Valérie Edmond, et al.
Blood|October 22, 2015
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutationsEmmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, et al.
Thrombosis and Haemostasis|August 14, 2018
Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic FeaturesAnna Guadall, Elodie Lesteven, Gil Letort, et al.
Haematologica|September 7, 2019
Synergistic effects of PRIMA-1<sup>Met</sup> (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemiaNabih Maslah, Norman Salomao, Louis Drevon, et al.
Pageof 4